Enveric Biosciences, Inc. (Nasdaq: ENVB) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application related to their new chemical entity (NCE) psilocin prodrug, known as EB-373. This prodrug is being developed by the company for the treatment of anxiety disorder. 

The patent, titled "C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using," encompasses composition of matter claims for a range of novel prodrug derivatives of psilocin, including the promising EB-373.

$ENVB is currently trading at $3.41, reflecting a significant increase of $1.89 (+125.08%).

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced pre-clinical data showcasing the potential of using INTASYL to silence TIGIT and CBL-B, which can enhance the anti-tumor response of natural killer (NK) cells. This development presents a more effective cell therapy option for treating cancer. NK cells are crucial components of the body's defense mechanism against cancerous cells.

$PHIO is presently trading at $4.72, indicating a rise of $0.96 (+25.53%).

Evercore ISI has upgraded Teva Pharmaceutical Industries Limited's (NYSE: TEVA) rating from In-line to Outperform.

In addition, Teva Pharmaceutical has unveiled a new strategic framework consisting of four main pillars to position the company for a new phase of growth. Teva's President and CEO, Richard Francis, outlined that the company's strategy is centered around achieving short- and long-term growth through its commercial portfolio and biosimilars, innovative pipeline, generics powerhouse, and focused capital allocation.

$TEVA is currently trading at $8.28, with a slight increase of $0.15 (+1.91%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)